AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 23rd, 2023 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of January 1, 2023 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Douglas Manion (“Executive”).
CONSULTING SERVICES AGREEMENTConsulting Services Agreement • February 23rd, 2023 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
THIS CONSULTING SERVICES AGREEMENT (this “Agreement”), is made and entered into as of January 1, 2023 (the “Effective Date”), by and between Aclaris Therapeutics, Inc., a Delaware corporation, with an address of 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087 (together with its wholly owned subsidiaries, the “Company”) and Frank Ruffo, an individual, with an address of (“Consultant”).
December 9, 2022 Frank Ruffo RE: Separation Agreement and General Release Dear Frank,Separation Agreement and General Release • February 23rd, 2023 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
This letter is intended to set forth the terms of your separation from employment with Aclaris Therapeutics, Inc. and your general release and waiver of claims in favor of Aclaris Therapeutics, Inc., and its parents, subsidiaries, affiliates, and all related corporate entities and partnerships, and their current or former officers, directors, partners, shareholders, members, representatives, agents, employees, predecessors, successors, and assigns (“Aclaris”).
